UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdi ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & CEO Russell Skibsted - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Yi Chen - H.C. Wainwright & Co., LLC Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences 2022 Financial Results Conference Call. At this time, all participants are in a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (State or other jurisdiction ...

Financial Data and Key Metrics Changes - The company reported revenue of $13.6 million for Q3 2022, an 11% increase compared to Q3 2021, but negatively impacted by currency fluctuations which reduced revenue by approximately $800,000 [6][15] - Year-to-date consolidated net revenues were $40.1 million, representing an 18% growth compared to $34 million in the same period of 2021, with a currency-adjusted growth of 23.5% [6][19] - The adjusted EBITDA loss for Q3 2022 was $2.5 million, compared to a loss of $1.1 million in Q3 2021 [18] Business Line Data and Key Metrics Changes - U.S. segment revenues increased by 27% to $8.9 million in Q3 2022, with end-user demand reaching a record of 1,061 units, up from 837 units in Q3 2021 [7][15] - International segment revenues decreased to $4.7 million, down approximately 10% year-over-year, but currency-adjusted revenue was up 6% [10][16] - End-user demand in the international segment grew 16% year-to-date compared to the prior year [10] Market Data and Key Metrics Changes - The U.S. segment's end-user demand was driven by a focus on face-to-face interactions with customers, resulting in significant growth [7] - The international segment's performance was affected by varying recovery rates across different countries, with expectations for growth in 2023 [10] Company Strategy and Development Direction - The company aims to expand the Challenge '22 program to five sales regions to enhance focus on key accounts and improve collaboration [8] - Strategic growth opportunities include expanding ILUVIEN's use for non-infectious posterior uveitis, with reimbursement obtained in six European countries [11] - The company is committed to rationalizing operating expenses to achieve sustainable positive EBITDA and cash flow [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow-neutral to positive status in 2023, supported by reduced operating expenses [29] - The company anticipates that the ongoing NEW DAY study and upcoming studies will enhance ILUVIEN's visibility and utility in treating retinal diseases [22] Other Important Information - The company plans to limit cash operating expenditures to less than $12 million per quarter in 2023, representing a 15% decrease [19] - The company is working with its lender to address the classification of $21 million in debt as current due to upcoming amortization [36] Q&A Session Summary Question: Risks associated with decreasing investments - Management believes that focusing on face-to-face engagement with physicians will sustain sales growth despite cuts in other areas [25][27] Question: Expectations for cash flow in 2023 - Management expects to achieve cash flow-neutral to positive status in 2023 based on projected expenses and moderate growth [29] Question: Changes in sales force structure - No disruption is expected; the company will maintain the number of territories while increasing regional directors for better focus on key accounts [31] Question: Monthly performance in Q3 - Q3 showed inconsistent performance with strong July and August, followed by a drop in September, attributed to competition from new products [34] Question: Timeline for clinical studies - The DRCR study is anticipated to take two years for enrollment, while the NEW DAY study aims for data availability in 2024 [39]

Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2022 Earnings Conference Call July 27, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Yi Chen - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Science Second Quarter 2022 Financial Results and Corporate Update Conference Ca ...

Financial Data and Key Metrics Changes - Consolidated revenue for Q1 2022 was $11.9 million, up 6% compared to Q1 2021 [7][20] - U.S. net revenue increased by 23% to $6.9 million from $5.6 million in the same period last year [20] - Adjusted EBITDA loss was $3.1 million in Q1 2022, compared to a loss of $1.3 million in Q1 2021 [24] - Net loss for Q1 2022 was $6 million, compared to a net loss of $3.6 million in Q1 2021 [24] - Basic and diluted net loss per share for Q1 2022 was $0.85, compared to $0.63 in Q1 2021 [25] Business Line Data and Key Metrics Changes - U.S. end user demand grew 25% to 918 units in Q1 2022 compared to 737 units in Q1 2021 [7][20] - International segment sales decreased by 11% year-over-year to $5 million due to COVID-19 impacts [22] - End user demand in international distributor markets was up 9% in Q1 2022 versus Q1 2021 [15][22] Market Data and Key Metrics Changes - End user demand in the U.S. was up 30% year-to-date through April 2022 compared to the same period in 2021 [9] - Demand in Portugal was up 35% in Q1 2022 over the prior year [17] - The U.K. returned to growth at the end of April 2022 in a year-over-year comparison [17] Company Strategy and Development Direction - The company is focusing on increasing engagement with retina specialists and has restarted a direct-to-patient campaign to support growth [11][13] - Anticipated launches for non-infectious posterior uveitis in Portugal and France are expected to contribute to growth [27] - The company is controlling spending in European markets to align with current revenue levels [18][26] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing recovery from the pandemic across most markets and expects strong performance to continue throughout the year [7][27] - The company aims to achieve adjusted EBITDA break-even or better in future quarters to mitigate cash burn [26] - Management expressed confidence in returning to pre-COVID run rates by mid to late Q3 2022 [40] Other Important Information - The company is enrolling patients in the NEW DAY study, which is over 50% enrolled [19] - The company has received orders for approximately 2,300 units valued at over $6 million for 2022 from international distributors [15][22] Q&A Session Summary Question: How is the PALADIN data influencing physician habits post-pandemic? - Management indicated a shift in treatment approaches for diabetic macular edema is occurring, with increased recognition of the need for anti-inflammatory treatments alongside anti-VEGF therapies [31][32] Question: What is the impact of the FDA's new requirements on commercialization? - Management does not anticipate significant impacts on ILUVIEN's commercialization but is monitoring the situation closely [42] Question: What were the non-performing items in spending? - Management mentioned postponing certain investments in advisory boards and additional personnel until patient flow justifies those expenses [46][47] Question: Is the company still on track for 15% year-over-year growth? - Management confirmed they feel good about achieving that growth, despite some supply chain issues [48][49] Question: How is the sales team performing? - Management expressed satisfaction with the U.S. sales team performance, noting they are close to hitting targets consistently [51]